Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. [electronic resource]
Producer: 20101025Description: 181-8 p. digitalISSN:- 1573-7217
- Aged
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Breast Neoplasms -- complications
- Diphosphonates -- adverse effects
- Docetaxel
- Double-Blind Method
- Drug Synergism
- Female
- Genes, erbB-2
- Humans
- Incidence
- Jaw Diseases -- chemically induced
- Middle Aged
- Multicenter Studies as Topic -- statistics & numerical data
- Neoplasm Metastasis
- Oral Hygiene
- Osteonecrosis -- chemically induced
- Paclitaxel -- administration & dosage
- Prospective Studies
- Randomized Controlled Trials as Topic -- statistics & numerical data
- Taxoids -- administration & dosage
- Vinblastine -- administration & dosage
- Vinorelbine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.